Factor VIII

From Wikipedia, the free encyclopedia

(Redirected from Antihemophilic factor)
Jump to: navigation, search


Coagulation factor VIII, procoagulant component (hemophilia A)
PDB rendering based on 1d7p.
Available structures: 1d7p, 1iqd
Identifiers
Symbol(s) F8; AHF; DXS1253E; F8 protein; F8B; F8C; FVIII; HEMA
External IDs OMIM: 306700 MGI88383 Homologene49153
RNA expression pattern

More reference expression data

Orthologs
Human Mouse
Entrez 2157 14069
Ensembl ENSG00000185010 ENSMUSG00000031196
Uniprot P00451 Q684Q7
Refseq NM_000132 (mRNA)
NP_000123 (protein)
NM_007977 (mRNA)
NP_032003 (protein)
Location Chr X: 153.72 - 153.9 Mb Chr X: 71.43 - 71.64 Mb
Pubmed search [1] [2]

Factor VIII (FVIII) is an essential clotting factor. The lack of normal FVIII causes Hemophilia A, an inherited bleeding disorder.

This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.[1]


Contents

The gene for Factor VIII is located on the X chromosome (Xq28). The gene for factor VIII presents an interesting primary structure, as in one of its introns another gene is embedded.[2].

FVIII is a glycoprotein procofactor synthesized and released into the bloodstream by the endothelium. In the circulating blood, it is mainly bound to von Willebrand factor (vWF, also known as Factor VIII-related antigen) to form a stable complex. Upon activation by thrombin or factor Xa, it dissociates from the complex to interact with Factor IXa the coagulation cascade. It is a cofactor to Factor IXa in the activation of Factor X, which, in turn, with its cofactor Factor Va, activates more thrombin. Thrombin cleaves fibrinogen into fibrin which polymerizes and crosslinks (using Factor XIII) into a blood clot.

No longer protected by vWF, activated FVIII is proteolytically inactivated in the process (most prominently by activated Protein C and Factor IXa) and quickly cleared from the blood stream.

Factor VIII is synthesized predominantly in the vascular endothelium and is not affected by liver disease. In fact, levels usually are elevated in such instances.[3]

FVIII concentrated from donated blood plasma (Aafact), or alternatively recombinant FVIII can be given to hemophiliacs to restore hemostasis. Thus, FVIII is also known as Anti-hemophilic factor.

The transfer of a plasma byproduct into the blood stream of a patient with hemophilia often led to the transmission of diseases such as HIV and hepatitis B and C before purification methods were improved. In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy. In particular, some pharmaceutical companies such as Bayer sparked controversy by continuing to sell contaminated factor VIII after new heat-treated versions were available.[4]

  1. ^ Entrez Gene: F8 coagulation factor VIII, procoagulant component (hemophilia A).
  2. ^ Levinson B, Kenwrick S, Lakich D, Hammonds G, Gitschier J (1990). "A transcribed gene in an intron of the human factor VIII gene". Genomics 7 (1): 1–11. PMID 2110545. 
  3. ^ R. Rubin, L. Leopold (1998). Hematologic Pathophysiology. Madison, Conn: Fence Creek Publishing. ISBN 1-889325-04-X. 
  4. ^ 2 Paths of Bayer Drug in 80's: Riskier One Steered Overseas.

  • Gitschier J (1991). "The molecular basis of hemophilia A.". Ann. N. Y. Acad. Sci. 614: 89-96. PMID 1902642. 
  • White GC, Shoemaker CB (1989). "Factor VIII gene and hemophilia A.". Blood 73 (1): 1-12. PMID 2491949. 
  • Antonarakis SE, Kazazian HH, Tuddenham EG (1995). "Molecular etiology of factor VIII deficiency in hemophilia A.". Hum. Mutat. 5 (1): 1-22. doi:10.1002/humu.1380050102. PMID 7728145. 
  • Lenting PJ, van Mourik JA, Mertens K (1999). "The life cycle of coagulation factor VIII in view of its structure and function.". Blood 92 (11): 3983-96. PMID 9834200. 
  • Saenko EL, Ananyeva N, Kouiavskaia D, et al. (2003). "Molecular defects in coagulation Factor VIII and their impact on Factor VIII function.". Vox Sang. 83 (2): 89-96. PMID 12201837. 
  • Lollar P (2003). "Molecular characterization of the immune response to factor VIII.". Vox Sang. 83 Suppl 1: 403-8. PMID 12617176. 
  • Fay PJ (2004). "Activation of factor VIII and mechanisms of cofactor action.". Blood Rev. 18 (1): 1-15. PMID 14684146. 
  • Lavigne-Lissalde G, Schved JF, Granier C, Villard S (2005). "Anti-factor VIII antibodies: a 2005 update.". Thromb. Haemost. 94 (4): 760-9. doi:10.1160/TH05-04-0760. PMID 16270627. 
  • Fang H, Wang L, Wang H (2007). "The protein structure and effect of factor VIII.". Thromb. Res. 119 (1): 1-13. doi:10.1016/j.thromres.2005.12.015. PMID 16487577. 

Advanced Search
Included Web Search Engines


Safe Search

close

Top Matching Results

Occasionally Search.com will highlight specialized results that are based on the context of your query. Examples of specialized results include specific links to news, images, or video.

Top Matching Results may highlight information from other Search.com pages, content from the CNET Network of sites, or third party content. The listings are based purely on relevance. Search.com does not receive payment for listings in this section but our partners that provide this data may get paid for listing these products.

Sponsored Links

This section contains paid listings which have been purchased by companies that want to have their sites appear for specific search terms and related content. These listings are administered, sorted and maintained by a third party and are not endorsed by Search.com.

Search Results

Search.com sends your search query to several search engines at one time and integrates the results into one list which has been sorted by relevance using Search.com's proprietary algorithm. You can customize the list of search engines included in your metasearch from the preferences.

The search engines that are used in your metasearch may allow companies to pay to have their Web sites included within the results. To view the Paid Inclusion policy for a specific search engine, please visit their Web site. Search.com does not accept payment or share revenue with any search engine partner for listings in this section.